SCHEMBL6813468

SCHEMBL6813468

CCOC(=O)CCN(C(C)(C)C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(Cl)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 7/20 0.44
MAPT P10636 2/20 0.41
TP53 P04637 1/20 0.41
MMP13 P45452 7/20 0.40
MMP2 P08253 6/20 0.40
HTT P42858 1/20 0.40
BMP1 P13497 1/20 0.39
MMP9 P14780 3/20 0.39
ADAM17 P78536 2/20 0.39
POLB P06746 1/20 0.38
ABCB11 O95342 2/20 0.38
MMP3 P08254 1/20 0.38
MMP7 P09237 1/20 0.38
MMP10 P09238 1/20 0.38
MMP8 P22894 1/20 0.38
MMP14 P50281 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
HTR2A P28223 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6809658 0.90 MMP13 (0.50) MMP1MAPTMMP13MMP2MMP9
SCHEMBL6817940 0.89 MMP1 (0.48) MMP1MMP13MMP2BMP1MMP9
SCHEMBL7344377 0.82 SMN1; SMN2 (0.48) MMP1TP53MMP13MMP2HTT
SCHEMBL3921655 0.79 MMP2 (0.47) MMP1MMP13MMP2BMP1MMP9
SCHEMBL231737 0.78 MMP1 (0.55) MMP1MMP13MMP2MMP9ADAM17
SCHEMBL13898736 0.76 BMP1 (0.48) MMP1MMP13MMP2BMP1MMP9
SCHEMBL7412150 0.75 MMP13 (0.60) MMP1MMP13MMP2MMP9ADAM17
SCHEMBL13899011 0.75 LMNA (0.47) MMP1MMP13MMP2HTTBMP1
SCHEMBL6691163 0.75 MMP1 (0.65) MMP1MMP13MMP2BMP1MMP9
SCHEMBL6813516 0.73 MMP1 (0.54) MMP1MMP13MMP2MMP9ADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6417229-B1 ENZYME INHIBITORS PFIZER INC 2002-07-09 US claimed
EP-1088550-A1 alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders Pfizer Products Inc. (US) 2001-04-04 EP claimed
EP-1415984-A1 Aryloxyarylsulfonylamino hydroxamic acid derivatives Pfizer Products Inc. (US) 2004-05-06 EP disclosed
EP-1003720-B1 ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES PFIZER PROD INC (US) 2004-03-31 EP disclosed
US-6417229-B1 ENZYME INHIBITORS PFIZER INC 2002-07-09 US disclosed
US-6214872-B1 ANTIARTHRITIC AND ANTICARCINOGENIC AGENTS PFIZER INC. 2001-04-10 US disclosed
EP-1088550-A1 alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders Pfizer Products Inc. (US) 2001-04-04 EP disclosed
EP-1003720-A1 ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES Pfizer Products Inc. (US) 2000-05-31 EP disclosed
WO-1999007675-A1 ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES PFIZER PRODUCTS INC. (US) 1999-02-18 WO disclosed